Literature DB >> 8467440

Treatment of rapid cycling bipolar disorder with combination therapy of valproate and lithium.

V Sharma1, E Persad, D Mazmanian, K Karunaratne.   

Abstract

Over the past two decades there has been a great deal of interest in the use of anticonvulsants to treat a variety of primary psychiatric disorders. Valproate, one such anticonvulsant, has been found to be effective in the treatment of acute mania, mixed states and rapid cycling disorders. This paper presents the results of an open study with combination therapy of valproate and lithium in a series of nine patients (mean age = 50 years). These patients had previously been treated with various psychotropic agents, including a combination of carbamazepine and lithium. All but one patient showed marked or moderate improvement in their condition. Of particular interest was the observation that in three patients there was evidence of augmentation between valproate and lithium during the depressed phase of their illness. There was significant improvement in their depression within 24 to 48 hours of the addition of lithium to valproate. The combination therapy was very well-tolerated. It is concluded that valproate and lithium combination therapy provides a safe and effective alternative for the treatment of rapid cycling variant of bipolar illness.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8467440     DOI: 10.1177/070674379303800213

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  11 in total

1.  Predictors of non-stabilization during the combination therapy of lithium and divalproex in rapid cycling bipolar disorder: a post-hoc analysis of two studies.

Authors:  Keming Gao; David E Kemp; Zuowei Wang; Stephen J Ganocy; Carla Conroy; Marry Beth Serrano; Martha Sajatovic; Robert L Findling; Joseph R Calabrese
Journal:  Psychopharmacol Bull       Date:  2010

Review 2.  Polytherapy in bipolar disorder.

Authors:  Daniel Lin; Hiram Mok; Lakshmi N Yatham
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

3.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk
Journal:  Bipolar Disord       Date:  2018-03-14       Impact factor: 6.744

Review 4.  Using Lithium in Older Age Bipolar Disorder: Special Considerations.

Authors:  Jocelyn Fotso Soh; Sivan Klil-Drori; Soham Rej
Journal:  Drugs Aging       Date:  2019-02       Impact factor: 3.923

Review 5.  Assessment and treatment of bipolar disorder in the elderly.

Authors:  J H Eastham; D V Jeste; R C Young
Journal:  Drugs Aging       Date:  1998-03       Impact factor: 3.923

6.  The antibipolar drug valproate mimics lithium in stimulating glutamate release and inositol 1,4,5-trisphosphate accumulation in brain cortex slices but not accumulation of inositol monophosphates and bisphosphates.

Authors:  J F Dixon; L E Hokin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

Review 7.  Update on the Epidemiology, Diagnosis, and Treatment of Mania in Older-Age Bipolar Disorder.

Authors:  Peijun Chen; Annemiek Dols; Soham Rej; Martha Sajatovic
Journal:  Curr Psychiatry Rep       Date:  2017-08       Impact factor: 5.285

Review 8.  A report on older-age bipolar disorder from the International Society for Bipolar Disorders Task Force.

Authors:  Martha Sajatovic; Sergio A Strejilevich; Ariel G Gildengers; Annemiek Dols; Rayan K Al Jurdi; Brent P Forester; Lars Vedel Kessing; John Beyer; Facundo Manes; Soham Rej; Adriane R Rosa; Sigfried Ntm Schouws; Shang-Ying Tsai; Robert C Young; Kenneth I Shulman
Journal:  Bipolar Disord       Date:  2015-09-19       Impact factor: 6.744

9.  A randomized controlled trial comparing lithium plus valproic acid versus lithium plus carbamazepine in young patients with type 1 bipolar disorder: the LICAVAL study.

Authors:  Giovani Missio; Doris Hupfeld Moreno; Frederico Navas Demetrio; Marcio Gerhardt Soeiro-de-Souza; Fernando Dos Santos Fernandes; Vivian Boschesi Barros; Ricardo Alberto Moreno
Journal:  Trials       Date:  2019-10-26       Impact factor: 2.279

10.  A 5-Year Study of Lithium and Valproic Acid Drug Monitoring in Patients with Bipolar Disorders in an Italian Clinical Center.

Authors:  Marco Carli; Eleonora Risaliti; Mena Francomano; Shivakumar Kolachalam; Biancamaria Longoni; Guido Bocci; Roberto Maggio; Marco Scarselli
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.